Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group - PubMed (original) (raw)
. 1997 Jun 26;336(26):1855-9.
doi: 10.1056/NEJM199706263362602.
Affiliations
- PMID: 9197213
- DOI: 10.1056/NEJM199706263362602
Free article
Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group
M H Chang et al. N Engl J Med. 1997.
Free article
Abstract
Background: A nationwide hepatitis B vaccination program was implemented in Taiwan in July 1984. To assess the effect of the program on the development of hepatocellular carcinoma, we studied the incidence of this cancer in children in Taiwan from 1981 to 1994.
Methods: We collected data on liver cancer in children from Taiwan's National Cancer Registry, which receives reports from each of the country's 142 hospitals with more than 50 beds. Data on childhood liver cancer were also obtained from Taiwan's 17 major medical centers. To prevent the inclusion of cases of hepatoblastoma, the primary analysis was confined to liver cancers in children six years of age or older. Data were also obtained on mortality from liver cancer among children.
Results: The average annual incidence of hepatocellular carcinoma in children 6 to 14 years of age declined from 0.70 per 100,000 children between 1981 and 1986 to 0.57 between 1986 and 1990, and to 0.36 between 1990 and 1994 (P<0.01). The corresponding rates of mortality from hepatocellular carcinoma also decreased. The incidence of hepatocellular carcinoma in children 6 to 9 years of age declined from 0.52 for those born between 1974 and 1984 to 0.13 for those born between 1984 and 1986 (P<0.001).
Conclusions: Since the institution of Taiwan's program of universal hepatitis B vaccination, the incidence of hepatocellular carcinoma in children has declined.
Comment in
- Prevention of primary liver cancer by immunization.
Zuckerman AJ. Zuckerman AJ. N Engl J Med. 1997 Jun 26;336(26):1906-7. doi: 10.1056/NEJM199706263362610. N Engl J Med. 1997. PMID: 9197221 No abstract available.
Similar articles
- Hepatitis B vaccination in children: the Taiwan experience.
Ni YH, Chen DS. Ni YH, et al. Pathol Biol (Paris). 2010 Aug;58(4):296-300. doi: 10.1016/j.patbio.2009.11.002. Epub 2010 Jan 29. Pathol Biol (Paris). 2010. PMID: 20116181 - Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.
Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS; Taiwan Hepatoma Study Group. Chang MH, et al. J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55. doi: 10.1093/jnci/djp288. Epub 2009 Sep 16. J Natl Cancer Inst. 2009. PMID: 19759364 - Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems.
Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, Ni YH, Chen CJ, Chen DS; Taiwan Childhood HCC Study Group. Chang MH, et al. Clin Cancer Res. 2005 Nov 1;11(21):7953-7. doi: 10.1158/1078-0432.CCR-05-1095. Clin Cancer Res. 2005. PMID: 16278421 - Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.
Chien YC, Jan CF, Kuo HS, Chen CJ. Chien YC, et al. Epidemiol Rev. 2006;28:126-35. doi: 10.1093/epirev/mxj010. Epub 2006 Jun 16. Epidemiol Rev. 2006. PMID: 16782778 Review. - [Hepatocellular carcinoma: a preventable cancer].
Viviani S, Jack A, Bah E, Montesano R. Viviani S, et al. Epidemiol Prev. 1997 Apr-Jun;21(2):129-36. Epidemiol Prev. 1997. PMID: 9378180 Review. Italian.
Cited by
- Surveillance Imaging and GAAD/GALAD Scores for Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis.
Huang CF, Kroeniger K, Wang CW, Jang TY, Yeh ML, Liang PC, Wei YJ, Hsu PY, Huang CI, Hsieh MY, Lin YH, Huang JF, Dai CY, Chuang WL, Sharma A, Yu ML. Huang CF, et al. J Clin Transl Hepatol. 2024 Nov 28;12(11):907-916. doi: 10.14218/JCTH.2024.00172. Epub 2024 Oct 14. J Clin Transl Hepatol. 2024. PMID: 39544249 Free PMC article. - Enhancing insights into Global Cancer Statistics 2022: implications for cancer control.
Xu J, Wang R, Guan X. Xu J, et al. Sci China Life Sci. 2024 Oct 18. doi: 10.1007/s11427-024-2734-6. Online ahead of print. Sci China Life Sci. 2024. PMID: 39432206 No abstract available. - Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions.
Mak LY, Liu K, Chirapongsathorn S, Yew KC, Tamaki N, Rajaram RB, Panlilio MT, Lui R, Lee HW, Lai JC, Kulkarni AV, Premkumar M, Lesmana CRA, Hsu YC, Huang DQ. Mak LY, et al. Nat Rev Gastroenterol Hepatol. 2024 Aug 15. doi: 10.1038/s41575-024-00967-4. Online ahead of print. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39147893 Review. - External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.
Poynard T, Lacombe JM, Deckmyn O, Peta V, Akhavan S, Zoulim F, de Ledinghen V, Samuel D, Mathurin P, Ratziu V, Thabut D, Housset C, Fontaine H, Pol S, Carrat F. Poynard T, et al. Gastro Hep Adv. 2022 May 25;1(4):604-617. doi: 10.1016/j.gastha.2022.02.008. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39132068 Free PMC article. - Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy.
Tanabe KK, Zahrieh D, Strand CA, Hoshida Y, Flotte TJ, Della'Zanna G, Umar A, Chavin KD, Cleary S, Kubota N, Llovet JM, Patel T, Siegel C, Limburg PJ. Tanabe KK, et al. Gastro Hep Adv. 2024 Jan 29;3(3):426-439. doi: 10.1016/j.gastha.2024.01.009. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39131140 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical